Cardiogenic embolism in the cat

Area of Science:

• Veterinary Medicine
• Cardiology
• Thrombosis

Background:

• Cardiogenic embolism (CE), also known as saddle thrombus or feline arterial thromboembolism, is a significant cause of mortality in cats with heart disease.
• Despite decades of clinical observation, advancements in preventing or treating CE in cats have been limited.
• A lack of data identifying specific risk factors beyond underlying heart disease hinders proactive management.

Purpose of the Study:

• To review the current understanding of CE in cats as of 2015.
• To summarize clinical presentation, survival rates, and thrombotic risks associated with feline arterial thromboembolism.
• To discuss current and potential strategies for the prevention of cardiogenic embolism in cats.

Main Methods:

• Review of existing literature on feline cardiogenic embolism.
• Analysis of clinical data regarding presentation, survival, and risk factors.
• Evaluation of recent thromboprophylactic studies and antithrombotic drug development.

Main Results:

• The first prospective study on thromboprophylaxis in feline arterial thromboembolism has been completed.
• Challenges remain in developing species-specific antithrombotic drugs for cats.
• Identifying cats at high risk for CE beyond having heart disease is still an area needing more research.

Conclusions:

• Significant progress in preventing or improving outcomes for feline cardiogenic embolism is still needed.
• Further research and pharmaceutical focus are crucial for advancing feline arterial thromboembolism treatment and prevention.
• A comprehensive understanding of risk factors and effective thromboprophylaxis is essential for feline cardiac health.